文献速递肝肾功能剂量调整

司美格鲁肽单次给药在肾功能不全者中的药代动力学与耐受性

Pharmacokinetics and Tolerability of a Single Dose of Semaglutide, a Human Glucagon-Like Peptide-1 Analog, in Subjects With and Without Renal Impairment.
PubMed 文献 · Clin Pharmacokinet · 2017-01-01

主要终点为血药浓度-时间曲线下面积(AUC)。结果显示,轻中度肾功能不全及ESRD者的暴露量与肾功能正常者相似;重度肾功能不全者的平均暴露量较正常者高22%,其95%CI(1.02-1.47)超出预设范围(0.70-1.43),但校正性别、年龄和体重后各比较均在预设临床相关范围内,提示肾功能不全者可能无需调整剂量。

要点

  • 轻中度肾功能不全及ESRD者司美格鲁肽暴露量与肾功能正常者相似。
  • 重度肾功能不全者暴露量高22%,但校正性别、年龄、体重后差异在预设范围内。
  • 司美格鲁肽0.5 mg单次给药耐受性良好,提示肾功能不全者可能无需调整剂量。

核心结论

  • 校正性别、年龄和体重后,肾功能不全者与肾功能正常者的司美格鲁肽暴露量相似。
  • 司美格鲁肽0.5 mg耐受性良好,肾功能不全者可能无需调整剂量。

研究设计与样本

  • 各组单次皮下注射司美格鲁肽0.5 mg,主要终点为AUC(从0到无穷大)。

主要发现

  • 轻度、中度肾功能不全和ESRD受试者的司美格鲁肽暴露量与肾功能正常者相似。
  • 重度肾功能不全受试者的平均暴露量比肾功能正常者高22%,比值95%CI为1.02-1.47,超出预设范围0.70-1.43。
  • 校正性别、年龄和体重差异后,所有比较均在预设的临床相关范围内。
  • 各肾功能组中,肌酐清除率(CLCR)与司美格鲁肽暴露量或C max之间均无关系。
  • 血液透析似乎不影响司美格鲁肽的药代动力学。

关键数值与推荐

  • 重度肾功能不全组平均暴露量较正常组高22%,比值95%CI为1.02-1.47,超出预设范围0.70-1.43。
  • 校正性别、年龄和体重后,各比较均在预设临床相关范围内。

临床怎么用

  • 肾功能不全患者使用司美格鲁肽0.5 mg时可能无需调整剂量,但仍需关注重度肾功能不全者的暴露差异。

局限性

  • 单次给药设计,未评估多次给药或长期用药下的药代动力学与安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The pharmacokinetics and tolerability of semaglutide, a once-weekly human glucagon-like peptide-1 analog in development for the treatment of type 2 diabetes mellitus, were investigated in subjects with/without renal impairment (RI). METHODS: Fifty-six subjects, categorized into renal function groups [normal, mild, moderate, severe, and end-stage renal disease (ESRD)], received a single subcutaneous dose of semaglutide 0.5 mg. Semaglutide plasma concentrations were assessed ≤480 h post-dose; the primary endpoint was the area under the plasma concentration-time curve from time zero to infinity. RESULTS: Semaglutide exposure in subjects with mild/moderate RI and ESRD was similar to that in subjects with normal renal function. In subjects with severe RI, the mean exposure of semaglutide was 22% higher than in subjects with normal renal function, and the 95% confidence interval (1.02-1.47) for the ratio exceeded the pre-specified limits (0.70-1.43). When adjusted for differences in sex, age, and body weight between the groups, all comparisons were within the pre-specified clinically relevant limits. Across RI groups there was no relationship between creatinine clearance (CLCR) and semaglutide exposure, or between CLCR and semaglutide maximum plasma drug concentration (C max). Hemodialysis did not appear to affect the pharmacokinetics of semaglutide. No appreciable changes in safety parameters or vital signs and no serious adverse events were noted. One subject with severe RI reported two major hypoglycemic events. CONCLUSION: When adjusted for differences in sex, age, and body weight, semaglutide exposure was similar between subjects with RI and subjects with normal renal function. Semaglutide (0.5 mg) was well-tolerated. Dose adjustment may not be warranted for subjects with RI. CLINICALTRIALS. GOV IDENTIFIER: NCT00833716.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Marbury TC, Flint A, Jacobsen JB, et al. Pharmacokinetics and Tolerability of a Single Dose of Semaglutide, a Human Glucagon-Like Peptide-1 Analog, in Subjects With and Without Renal Impairment. Clin Pharmacokinet. 2017. PMID: 28349386. doi:10.1007/s40262-017-0528-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。